We are live on ! Find out more
FTXH icon

First Trust Nasdaq Pharmaceuticals ETF
FTXH

9 hedge funds and large institutions have $1.31M invested in First Trust Nasdaq Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more capital inflows, than outflows

Capital inflows: $302K | Capital outflows: $167K

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

1.92% more ownership

Funds ownership: 16.5% → 18.42% (+1.9%)

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$287K
2
Bank of America
Bank of America
North Carolina
+$10.3K
3
UBS Group
UBS Group
Switzerland
+$5.46K
4
Wells Fargo
Wells Fargo
California
+$21

Top Sellers

Rank Fund Capital Flow
1
Squar Milner Financial Services
Squar Milner Financial Services
California
-$119K
2
Jane Street
Jane Street
New York
-$39.7K
3
LPL Financial
LPL Financial
California
-$8.26K

FTXH Hedge Fund Activity: Q3 2019 in Review

9 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2019, worth a combined $1.31M — up 7.7% from $1.22M a quarter earlier.

Fund positioning in FTXH was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $287K. The largest seller was Squar Milner Financial Services, exiting entirely with an estimated $119K sold.

  • 9 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $1.31M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2019, up 7.7% quarter-over-quarter.
  • 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2019 and 1 closed out, a net change of 0 holders.
  • The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2019 was Citadel Advisors, an estimated $287K added.
  • The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2019 was Squar Milner Financial Services, an estimated $119K sold.

Based on aggregated 13F filings for Q3 2019.